EndpointsApr 241 min read

Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection

Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Medicines Agency’s ...

Apr 24, 2026read at Endpoints ↗

April 24, 2026 07:30 AM EDTUpdated 11:09 AM Pharma Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection Ayisha Sharma News Reporter Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗

85 words · retrieved Apr 26

sharex / twitter linkedin

Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection

comments(0)

Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection

comments(0)